Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

J Neurol Sci. 2001 Apr 1;185(2):119-22. doi: 10.1016/s0022-510x(01)00478-6.

Abstract

We report favorable results of the long term use of mycophenolate in the treatment of three patients with myasthenia gravis (MG), two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), one patient with secondary polymyositis (PM), and one patient with inclusion body myositis (IBM). Side effects were mild. Mycophenolate appears to be a useful addition to the armamentarium of immunosuppressants for treatment of chronic immunologically mediated neuromuscular diseases.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects
  • Chronic Disease
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / adverse effects
  • Male
  • Middle Aged
  • Myasthenia Gravis / drug therapy*
  • Myasthenia Gravis / immunology
  • Myasthenia Gravis / physiopathology
  • Mycophenolic Acid / administration & dosage*
  • Mycophenolic Acid / adverse effects
  • Mycophenolic Acid / analogs & derivatives
  • Myositis, Inclusion Body / drug therapy*
  • Myositis, Inclusion Body / immunology
  • Myositis, Inclusion Body / physiopathology
  • Polyneuropathies / drug therapy*
  • Polyneuropathies / immunology
  • Polyneuropathies / physiopathology
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Immunosuppressive Agents
  • Mycophenolic Acid
  • Prednisone